Merck (NYSE: MRK) reported third-quarter results last Friday. Results were generally mixed, with the stock down 8%. Financial results were adequate, with some lingering negative effects from a June cyber attack. Although Keytruda remains an incredibly successful and fast-growing drug, failing to gain European market access is a large setback. Besides directly reducing future earnings growth, it seems to have dampened the bull/growth perception around the company in the recent past.
Financial Results
Revenue growth decreased 2% YoY, and was $220 million below analyst expectations. Growth was lower than expected mainly due to a production shortage, to quote from the call:


